Institutional shares held 60.7 Million
22.3K calls
6K puts
Total value of holdings $1.94B
$713K calls
$191K puts
Market Cap $1.71B
53,495,300 Shares Out.
Institutional ownership 113.43%
# of Institutions 303


Latest Institutional Activity in SUPN

Top Purchases

Q4 2024
Principal Financial Group Inc Shares Held: 297K ($9.49M)
Q4 2024
Woodline Partners LP Shares Held: 424K ($13.6M)
Q4 2024
Raymond James Financial Inc Shares Held: 189K ($6.06M)
Q4 2024
Great Lakes Advisors, LLC Shares Held: 170K ($5.42M)
Q4 2024
D. E. Shaw & Co., Inc. Shares Held: 546K ($17.5M)

Top Sells

Q4 2024
Armistice Capital, LLC Shares Held: 4.84M ($155M)
Q4 2024
Polar Capital Holdings PLC Shares Held: 1.69M ($54M)
Q4 2024
Millennium Management LLC Shares Held: 30.5K ($975K)
Q4 2024
Schroder Investment Management Group Shares Held: 299K ($9.55M)
Q4 2024
Stephens Investment Management Group LLC Shares Held: 1.75M ($56M)

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.


Insider Transactions at SUPN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
613K Shares
From 17 Insiders
Grant, award, or other acquisition 43.2K shares
Exercise of conversion of derivative security 569K shares
Sell / Disposition
474K Shares
From 12 Insiders
Payment of exercise price or tax liability 88K shares
Open market or private sale 386K shares

Track Institutional and Insider Activities on SUPN

Follow SUPERNUS PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SUPN shares.

Notify only if

Insider Trading

Get notified when an Supernus Pharmaceuticals, Inc. insider buys or sells SUPN shares.

Notify only if

News

Receive news related to SUPERNUS PHARMACEUTICALS, INC.

Track Activities on SUPN